MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Hutchison China MediTech Limited Company Profile (LON:HCM)

Consensus Ratings for Hutchison China MediTech Limited (LON:HCM) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 1,750

Analysts' Ratings History for Hutchison China MediTech Limited (LON:HCM)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016Beaufort SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016Panmure GordonReiterated RatingUnder ReviewView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016Stifel NicolausInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Hutchison China MediTech Limited (LON:HCM)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Hutchison China MediTech Limited (LON:HCM)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Hutchison China MediTech Limited (LON:HCM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Hutchison China MediTech Limited (LON:HCM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
10/20/2015Nash,ChristopherInsiderBuy4,512GBX 2,195£99,038.40Tweet This Trade  Share This Trade on StockTwits
4/21/2015Christopher NashInsiderBuy1,388GBX 1,800£24,984Tweet This Trade  Share This Trade on StockTwits
4/15/2015Simon ToInsiderBuy28,000GBX 1,585£443,800Tweet This Trade  Share This Trade on StockTwits
4/10/2015Simon ToInsiderBuy25,000GBX 1,421.50£355,375Tweet This Trade  Share This Trade on StockTwits
4/7/2015Edith ShihInsiderBuy2,000GBX 1,385£27,700Tweet This Trade  Share This Trade on StockTwits
4/2/2015Simon ToInsiderBuy10,000GBX 1,385£138,500Tweet This Trade  Share This Trade on StockTwits
4/1/2015Edith ShihInsiderBuy15,000GBX 1,365£204,750Tweet This Trade  Share This Trade on StockTwits
3/30/2015Edith ShihInsiderBuy13,000GBX 1,300£169,000Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Hutchison China MediTech Limited (LON:HCM)
DateHeadline
06/21/16 04:07 PMBeaufort Securities Breakfast Alert: GlaxoSmithKline, Hutchison China Meditech, Imperial Innovations
06/21/16 04:07 PMHutchison China Meditech Ltd (LON:HCM) price target maintained to GBX0 as issued in a report today by Beaufort Securities
06/20/16 10:37 AMChi-Med initiation of phase II trial of savolitinib
06/20/16 10:37 AMHutchison China MediTech : Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
06/20/16 10:37 AMHutchison China Meditech Limited: Savolitinib Global Phase II Trial Initiated
06/20/16 10:37 AMHutchison China Meditech Ltd (LON:HCM) price target held steady to GBX0 as reported today by Panmure Gordon
03/22/16 10:01 AMHutchison China MediTech Limited Announces Closing Of U.S. Public Offering Of ADSs Raising Approximately US$101 Million On The Nasdaq Stock Market - Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the closing of its U.S. public offering of American depositary shares ("ADSs") (the "Offering"). The Offering raised gross proceeds of US$101,250,000, through the sale of 7,500,000 ...
03/14/16 01:26 PMUpcoming IPO Calendar: This Week's Deals Include 3 Biotechs (HCM, SENS, SBPH) - Money Morning - Money MorningUpcoming IPO Calendar: This Week's Deals Include 3 Biotechs (HCM, SENS, SBPH)Money Morning1: Hutchison China MediTech Ltd. (Nasdaq: HCM) is a Chinese developer of oncology and cancer treatments. The biotech's majority owner is CK Hutchison Holdings, a Hong Kong-based international conglomerate with businesses in more than 50 nations ...
03/14/16 03:33 AMHutchison China MediTech Ltd. breached its 50 day moving average in a Bullish Manner : HCM-GB : March 14, 2016 -
03/04/16 12:13 PMHutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs - [Business Wire] - LONDON--(BUSINESSWIRE)-- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM.L - News) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the form of American depositary shares (“ADSs”) in the United States (the “Offering”). Chi-Med intends to grant the underwriters a 30-day option to purchase additional ADSs in connection with the potential Offering at the final offering price.
03/02/16 01:44 AMChi-Med initiates sulfatinib Phase II clinical trial in thyroid cancer -
03/01/16 06:07 AMFull Year 2015 Hutchison China MediTech Ltd Earnings Release - Time Not Supplied -
02/26/16 11:02 AMWere Analysts Bullish Hutchison China MediTech Limited (LON:HCM) This Week? - Clinton Financial - Were Analysts Bullish Hutchison China MediTech Limited (LON:HCM) This Week?Clinton FinancialOut of 1 analysts covering Hutchison China Meditech Ltd (LON:HCM), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Hutchison China Meditech Ltd was the topic in 5 analyst reports since July 28, 2015 according to ...
02/26/16 11:02 AMHUTCHISON CHINA MEDITECH LIMITED - Hutchison China MediTech Ltd. is a holding company, which engages in the research and develops, manufactures, and sells pharmaceuticals and health oriented consumer products.It operates through the following business segments: China Healthcare, Drug ...
02/15/16 01:35 PMHow Many Hutchison China MediTech Limited (LON:HCM)'s Analysts Are Bullish? - Sonoran Weekly Review - How Many Hutchison China MediTech Limited (LON:HCM)'s Analysts Are Bullish?Sonoran Weekly ReviewOut of 1 analysts covering Hutchison China Meditech Ltd (LON:HCM), 0 rate it “Buy”, 1 “Sell”, while 0 “Hold”. This means 0% are positive. Hutchison China Meditech Ltd was the topic in 5 analyst reports since July 28, 2015 according to ...
02/15/16 01:35 PMUpdated: Hutchison, Tianjin Bank, GoAir gear up for IPOs - Chinese pharmaceutical company Hutchison China MediTech (Chi-Med) has picked a quartet of co-managers ... globalcapital.com Or sign up for a trial to gain full access to the entire site for a limited period. Already Registered? Email* Password* Remember ...
02/15/16 01:35 PMWeek In Review: China Resource Plans $1 Billion Hong Kong IPO - Hutchison China MediTech (Chi-Med) (Pending:HCM) filed a third iteration of a prospectus for its $100 million IPO in the US, which still doesn't include final pricing. Strictly speaking, the offering is an IPO of new ADS shares. These will be some multiple ...
02/14/16 12:52 PMIs Hutchison China MediTech Limited a Sell? The Stock Declines Again - Sonoran Weekly Review - Is Hutchison China MediTech Limited a Sell? The Stock Declines AgainSonoran Weekly ReviewThe stock of Hutchison China MediTech Limited (LON:HCM) is a huge mover today! The stock is up 2.78% or GBX 56.08 after the news, hitting GBX 2073.58 per share. About 1,898 shares traded hands. Hutchison China MediTech Limited (LON:HCM) has ...
02/09/16 01:28 PMRecent Broker Updates On Hutchison China Meditech Ltd (LON:HCM) - Risers & Fallers - Recent Broker Updates On Hutchison China Meditech Ltd (LON:HCM)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Hutchison China Meditech Ltd (LON:HCM). The latest broker reports which are currently outstanding on Tuesday 9th February state 0 analysts have a rating of “strong buy”, ...
01/29/16 02:15 AMNotice of Announcement of 2015 Final Results - [at noodls] - London: Friday, 29 January 2016: Hutchison China MediTech Limited ('Chi-Med') (AIM:HCM) will be announcing its final results for the year ended 31 December 2015 on Tuesday, 1 March 2016. An analyst presentation ...
01/26/16 12:30 PMWhat Do Analysts Think Of Hutchison China Meditech Ltd (LON:HCM) This Week? - Risers & Fallers - What Do Analysts Think Of Hutchison China Meditech Ltd (LON:HCM) This Week?Risers & FallersCurrently 0 brokers are covering Hutchison China Meditech Ltd (LON:HCM), 0 rate it “Strong Buy”, 0 “Buy”, 0 “Sell”, 0 “Strong Sell”, while 0 “Neutral”. Below are the most recently updated broker updates which include ratings and price targets for ...
01/19/16 03:32 AMHutchison China MediTech Ltd. breached its 50 day moving average in a Bearish Manner : January 19, 2016 -
01/15/16 04:59 AMChi-Med initiates HMPL-523 Phase I clinical trial in hematological cancer in Australia - [Business Wire] - LONDON--(BUSINESSWIRE)-- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM.L - News) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated a Phase I trial in Australia in patients with hematological malignancies. This trial follows the successful completion of a first-in-human Phase I clinical trial in healthy volunteers in October 2015. The new study is a Phase I, open-label, dose escalation study of HMPL-523 as monotherapy administered orally to patients with relapsed or refractory hematological malignancies who are unable to tolerate standard therapy or for whom there is no effective therapy.
01/08/16 03:30 AMHutchison China MediTech Ltd. breached its 50 day moving average in a Bullish Manner : January 8, 2016 -
12/18/15 01:02 AMInitiation of Sulfatinib Phase III Registration Study in Neuroendocrine Tumor Patients - [PR Newswire] - Hutchison China MediTech Limited ("Chi-Med") (HCM.L) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract. SANET-ep is a randomized, double-blind, placebo-controlled, multi-center Phase III sulfatinib registration study to treat pathologically low or intermediate grade NET patients whose disease has progressed, locally advanced or distant metastasized and for whom there is no effective therapy. Patients will be randomized at a 2:1 ratio to receive either 300 milligrams of sulfatinib orally once per day, or placebo, on every 28-day treatment cycle. The primary objective of this study is to evaluate the progression-free survival of sulfatinib as compared to that of placebo, with secondary endpoints including objective response rate ("ORR"), disease control rate, time to response, duration of response, overall survival, safety and tolerability.
12/09/15 01:00 AMUS$105 Million Shanghai Land Compensation Agreement - [PR Newswire] - Hutchison China MediTech Limited ("Chi-Med") (HCM.L) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its 50:50 joint venture with a subsidiary of Shanghai Pharmaceuticals Holding Co., Limited, has today entered into an agreement (the "Agreement") with the Shanghai government for the surrender of SHPL's remaining 36 years land-use rights on its approximately 58,000 square metres old factory site at 2098 Zhennan Road, Taopu Town, Putuo District, Shanghai (the "Site"). The Agreement signed between SHPL and (i) Land Development Centre of Putuo District of Shanghai Municipality and (ii) Shanghai Taopu Smart City of Science and Technology Development and Construction Company Limited (together the "Acquirers") provides that SHPL will return the Site to the Acquirers in consideration for cash compensation of approximately US$105 million (the "Compensation").
12/08/15 02:03 AMInitiation of Fruquintinib Phase III Registration Trial in Non-small Cell Lung Cancer - [PR Newswire] - LONDON, December 8, 2015 /PRNewswire/ -- Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, ...
11/10/15 06:16 AMResults of Extraordinary General Meeting - [at noodls] - Results of Extraordinary General Meeting
11/09/15 02:16 AMDirector's Share Dealing - [at noodls] - London: Monday, 9 November 2015: Hutchison China MediTech Limited ('Chi-Med') (AIM: HCM) hereby makes the following amendments to the '' announcement released on 20 October 2015 subsequent to the notification ...
11/06/15 01:00 AMChi-Med Initiates Sulfatinib U.S. Clinical Trials - [PR Newswire] - LONDON, November 6, 2015 /PRNewswire/ -- Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, ...
10/30/15 02:57 AMCompletion of Phase I Clinical Trial of Novel Syk Inhibitor HMPL-523 for Autoimmune Diseases in Healthy Volunteers - [PR Newswire] - LONDON, October 30, 2015 /PRNewswire/ -- Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, ...
10/30/15 02:41 AMSulfatinib Clinical Results and Fruquintinib-Savolitinib Combination Preclinical Results to be Presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference - [PR Newswire] - LONDON, October 30, 2015 /PRNewswire/ -- Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, ...
10/27/15 05:05 AMHutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing - [at noodls] - Press Release London: Friday, 16 October 2015: Hutchison China MediTech Limited ('Chi-Med') (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the 'Registration ...
10/23/15 01:46 AMProof-of-concept Study of Fruquintinib in Non-small Cell Lung Cancer Triggers Milestone Payment - [PR Newswire] - LONDON, October 23, 2015 /PRNewswire/ -- Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, ...
About Hutchison China MediTech Limited

Hutchison China MediTech Limited logoHutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: HCM
  • CUSIP:
Key Metrics:
  • Previous Close: $27.61
  • 50 Day Moving Average: $1838.38
  • 200 Day Moving Average: $2148.77
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.06B
  • Current Quarter EPS Consensus Estimate: $0.12 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha